Clinical efficacy of budipine in Parkinson's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 56, 1999, Pages 75-82

  Przuntek, H ^a   Muller T ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUDIPINE; LEVODOPA; ANTIPARKINSON AGENT; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; ANIMAL; CLINICAL TRIAL; HUMAN; REVIEW;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS; HUMANS; PARKINSON DISEASE; PIPERIDINES;

EID: 0032588326     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6360-3_3     Document Type: Conference Paper

References (26)

1. Bonnet AM, Loria Y, Saint Hilaire MH, Lhermitte F, Agid Y (1987) Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 37: 1539-1542
2. Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH (1995) Nigral and extranigral pathology in Parkinson's disease. J Neural Transm [Suppl] 46: 15-32
3. Chase TN, Engber TM, Mouradian MM (1996) Contribution of dopaminergic and glutaminergic mechanisms to the pathogenesis of motor response complications. Adv Neurol 69: 497-501
4. Fahn S (1996) Is Levodopa toxic? Neurology 47 [Suppl 3]: 184-195
5. Fahn S (1997) Levodopa-induced neurotoxicity: does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 8(5): 376-393
6. Hacknack G, Menge HG, Eistetter K, Krüger U, Schäefer H, Klosa J (1979) 4,4-Diphenylpiperidine- ein neuer Substanztyp für die Therapie des Morbus Parkinson, Österr Chemie Z 4: 61-62
7. Jackisch R, Huang HY, Reimann W, Limberger N (1993) Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro. J Pharmacol Exp Ther 264: 889-898
8. Jackisch R, Kruchen A, Sauermann W, Hertting G, Feuerstein TJ (1994) The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists. Eur J Pharmacol 264: 207-211
9. Jellinger K (1999) Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms? J Neural Transm [Suppl] 56: 1-29
10. Jellinger K, Bliesath H (1987) Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo. J Neurol 234: 280-282
11. Klockgether T, Jacobsen P, Loschmann PA, Turski L (1993) The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm [PD-Sect] 5: 101-106
12. Kornhuber J, Herr B, Thome J, Riederer P (1995) The antiparkinsonian drug budipine binds to NMDA and sigma receptors in post mortem brain tissue. J Neural Transm [Suppl] 46: 131-137
13. Menge H, Brand U (1982) Zusammenfassende Darstellung der Pharmakologie von Budipin, einem neuen 4,4 Diphenylpiperidinderivat für die Parkinson-Therapie, Drug Res 32: 85-98
14. Menge HG, Brand U (1985) Pharmacologic bases of antiparkinsonian therapy. In: Gerstenbrand K, Poewe W, Stern G. (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 82-92
15. Mihatsch W, Russ H, Przuntek H (1988) Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine. J Neural Transm 71: 177-188
16. 3H)GBR-12935 binding proteins. Arch Biochem Biophys 276: 424-432
17. Przuntek H, Russ H (1985) Budipine and the MPTP binding site. Lancet 2: 35-36
18. Przuntek H, Stasch JP (1984) Biochemical and pharmacologic aspects of the mechanism of action of budipine. In: Gerstenbrand F, Poewc W, Stern G. (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 106-111
19. Przuntek H, Russ H, Henning K, Pindur U (1985). The protective effect of 1-tert,butyl-4.4-diphenylpiperidine against the nigrostriatal neurodegeneration caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 37: 1195-1200
20. Russ H, Pindur U, Przuntek H (1986) The interaction of 1-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site. J Neural Transm 65: 157-166
21. Schaefer H, Hackmack G, Eistetter K, Kruger U, Menge HG, Klosa J (1984) Synthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines. Arzneimittelforschung 34: 233-240
22. Siegfried J, Fischer R (1985) Budipine: A new chemical substance in the treatment of Parkinson's disease. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 153-157
23. Spieker S, Löschmann P, Jentges C, Boose A, Klockgether T, Dichgans J (1995) Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings. Clin Neuropharmacol 18(3): 266-272
24. Spieker S, Breit S, Klockgether T, Dichgans J (1999) Tremorlytic activity of budipine in Parkinson's disease. J Neural Transm [Suppl] 56: 165-172
25. Stasch JP, Russ H, Schacht U, Witteler M, Neuser D, Gerlach M, Leven M, Kuhn W, Jutzi P, Przuntek H (1988) 4,4-Diphenylpiperidine derivates and their sila analogues. A comparative study of their interaction with neural receptor binding sites and synaptosomal monoamine uptake. Arzneimittelforschung 38: 1075-1078
26. Verhagen Metman L, Del Dotto P, van den Munckhof BS, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50: 1323-1326